Designing a Long Acting Erythropoietin
Author Information
Author(s): Fares Fuad, Havron Avri, Fima Eyal
Primary Institution: University of Haifa and ModigeneTech
Hypothesis
The addition of 12 O-linked oligosaccharide chains to the backbone of EPO will dramatically increase the longevity of EPO.
Conclusion
The study found that the new EPO analog EPO-(CTP)3 significantly increased haematocrit levels and reticulocyte counts compared to traditional EPO treatments.
Supporting Evidence
- EPO-(CTP)3 increased haematocrit levels by approximately 8 folds compared to rHuEPO.
- EPO-(CTP)3 had a longer circulatory half-life than both rHuEPO and Aranesp.
- The in vitro activity of EPO-(CTP)3 was similar to that of EPO-WT and commercial rHEPO.
Takeaway
Scientists created a new version of a hormone that helps make red blood cells, and it works better and lasts longer in the body than the old version.
Methodology
The study involved creating a new EPO variant by fusing carboxyl-terminal peptides to its coding sequence, followed by testing its effects in vitro and in vivo on mice.
Limitations
The therapeutic efficacy of EPO-CTP analog needs to be established in higher animals and in human clinical trials.
Participant Demographics
Male ICR mice were used for the in vivo studies.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website